Creative Life Science (啟新生技) reported a fiscal year 2025 tax-after-profit of NT$118 million (+24.7% YoY) and an EPS of NT$5.31, marking a three-year high. The company is now officially preparing for its IPO filing in 2026.

• Dual-Engine Growth: Revenue reached NT$1.098 billion in 2025, a record high driven by proprietary microbial reagents and integrated testing services.
• Regenerative Medicine Infrastructure: The company’s new Hsinchu BioMedical Science Park facility has recently commenced operations. Designed to PIC/S GMP standards, the plant will produce cell culture media and critical reagents, strengthening CMP's position in the regenerative medicine supply chain.
• International Expansion: Through a partnership with ESCO, CMP is actively scaling its diagnostics and testing services into the Southeast Asian market, leveraging Taiwan's mature bio-manufacturing expertise.

Resource:啟新生技去年EPS 5.31元創近三年新高，目標今年上市櫃